WSW, NY, December 15th, 2025, FinanceWire
Silexion Therapeutics (NASDAQ: SLXN) has been initiated with coverage by Litchfield Hills Research, which assigned a Buy rating and a 12-month price target of $6 in a report dated December 15, 2025. These views and projections are those of Litchfield Hills Research and its analyst team, not of Silexion Therapeutics. The full report is available directly from Litchfield Hills Research. As of the market close on December 12, 2025, SLXN was trading at $2.81 per share.
A Closer Look at Silexion Therapeutics
Silexion Therapeutics is developing RNA interference (RNAi) therapies aimed at KRAS-driven cancers – among the most prevalent and historically difficult-to-treat oncogenic drivers in solid tumors such as pancreatic, colorectal, and lung cancers. Despite decades of research, direct and durable targeting of KRAS signaling has remained elusive outside a narrow set of variants, leaving a large unmet need across oncology.
The company’s lead program, SIL204, seeks to address this gap by silencing KRAS transcripts before mutant proteins are produced. While the first wave of targeted therapies has focused predominantly on the KRAS G12C variant, which represents only a small fraction of pancreatic cancer cases, SIL204 has demonstrated preclinical activity against eight major KRAS mutations – across multiple human cell lines derived from five organ sites. Such breadth at the RNA level suggests the potential to address a wider spectrum of KRAS-driven tumors than current small molecules can. The underlying RNAi platform has also shown activity in colorectal, lung, and gastric cancer models, underscoring its versatility beyond pancreatic cancer.
This suite of activity aligns with the broader market reality: KRAS mutations are among the most common oncogenic alterations in cancer, and most variants still lack broadly effective clinical interventions despite extensive efforts by academia and industry. By suppressing mutant KRAS expression upstream, Silexion’s approach offers a fundamentally different mechanism of action, with the potential to impact both primary and metastatic disease.
Silexion’s development strategy builds on clinical precedent. Its first-generation product, LODER, demonstrated encouraging Phase 2 results in locally advanced pancreatic cancer in combination with chemotherapy, including a 9.3-month improvement in overall survival. SIL204 incorporates enhanced delivery and broader mutation coverage informed by this earlier work.
The commercial opportunity, while still emerging, is meaningful. Market research estimates the global locally advanced pancreatic cancer (LAPC) market at approximately $1.3 billion in 2024, with expectations for continued growth over the coming decade – an anchor indication for Silexion’s planned Phase 2/3 program.
At the same time, the oncology landscape more broadly is experiencing a resurgence of strategic investment activity. Large pharmaceutical companies have recently executed multi-billion-dollar acquisitions and collaborations to bolster their cancer portfolios and gain access to novel mechanisms and multi-indication platforms – such as Johnson & Johnson’s (NYSE: JNJ) ~$3.05 billion acquisition of Halda Therapeutics, a clinical-stage oncology innovator, and high-value KRAS-focused collaborations in the industry. Such deal-making underscores that major players are willing to pay premium valuations for assets that address core oncogenic drivers and exhibit platform-like potential, reinforcing the attractiveness of differentiated therapeutic approaches in solid tumor oncology.
Despite trading at a market capitalization of under $9 million, Silexion is advancing a KRAS-targeting paradigm with broad preclinical validation and a clear regulatory path forward, including planned submissions in Israel expected any day now and in Germany and the EU in Q1 2026 and the initiation of Phase 2/3 clinical trials in Q2 2026.
Recent News Highlights from Silexion
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire has received cash compensation from Silexion Therapeutics Corp for promotional media services, which are provided on an ongoing basis. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. References to analyst ratings, price targets, market size estimates, or other third-party data are provided strictly for informational purposes. The analyst price target initiation report metnioned is subject to its own disclosures and disclaimers which readers should review. Neither Wall Street Wire nor the issuer endorse, confirm, or guarantee the accuracy of such information. This article should not be considered an official communication of the issuer.